Status:
COMPLETED
Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Lantheus Medical Imaging
Conditions:
Pulmonary Embolism
Eligibility:
All Genders
18+ years
Brief Summary
The use of the contrast agent, Ablavar, will help with the diagnosis of pulmonary embolism in magnetic resonance imaging (MRI).
Detailed Description
Specific Aim 1: To assess first-pass SNR and CNR of pulmonary MR angiography performed with 0.03 mmol/Kg of intravenous gadofosveset trisodium. Hypothesis: Use of 0.03 mmol/Kg of gadofosveset trisodi...
Eligibility Criteria
Inclusion
- Patient that have pulmonary embolism.
- 18 yrs of age and older
Exclusion
- allergy to gadolinium based contrast.
- allergy to iodated based contrast.
- renal insufficiency (GFR \< 60 mL/min?1.73m2)
- pregnant or nursing
- contraindication to MRI
Key Trial Info
Start Date :
July 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01165892
Start Date
July 1 2011
End Date
April 1 2013
Last Update
March 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.